Predictive Factors for Response to Neoadjuvant Therapy in Breast Cancer

被引：23

作者：

Loibl, Sibylle ^{[1
,2
]}

von Minckwitz, Gunter ^{[1
,3
]}

Untch, Michael ^{[4
]}

Denkert, Carsten ^{[5
]}

机构：

[1] German Breast Grp, Neu Isenburg, Germany

[2] Sana Klinikum, Offenbach, Germany

[3] Univ Womens Hosp, Frankfurt, Germany

[4] HELIOS Kliniken Berlin Buch, Frauenklin, Interdisziplinares Brustzentrum, Berlin, Germany

[5] Charite, Inst Pathol, Berlin, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷 / 10期

基金：

欧盟第七框架计划;

关键词：

Breast cancer; Neoadjuvant therapy; Biomarker; Predictor; INTERNATIONAL EXPERT CONSENSUS; TUMOR-INFILTRATING LYMPHOCYTES; PATHOLOGICAL COMPLETE RESPONSE; CHEMOTHERAPY PLUS TRASTUZUMAB; RANDOMIZED PHASE-II; OPEN-LABEL; PREOPERATIVE CHEMOTHERAPY; SYSTEMIC TREATMENT; LAPATINIB; SURVIVAL;

D O I：

10.1159/000367643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Within 2 decades, neoadjuvant therapy (NAT) has become a standard treatment option in breast cancer. The advantage of NAT is the ability to monitor the treatment effect. Pathological complete response (pCR) after NAT is a very good predictor for long-term outcome. Clinical factors, such as age and body mass index, as well as recently identified biomarkers can predict the chance of achieving a pCR. Hormone-receptor status, proliferation markers, immune infiltrates and genetic alterations, such as germline BRCA and PIK3CA, can now be measured almost on a routine basis due to the decreased analysis costs.

引用

页码：563 / 568

页数：6

共 63 条

[1] Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience [J].

Arun, Banu ;

Bayraktar, Soley ;

Liu, Diane D. ;

Barrera, Angelica M. Gutierrez ;

Atchley, Deann ;

Pusztai, Lajos ;

Litton, Jennifer Keating ;

Valero, Vicente ;

Meric-Bernstam, Funda ;

Hortobagyi, Gabriel N. ;

Albarracin, Constance .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (28) :3739-3746

[2]

Baselga J, 2013, EUR J CANCER, V49, pS402

[3] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].

Baselga, Jose ;

Bradbury, Ian ;

Eidtmann, Holger ;

Di Cosimo, Serena ;

de Azambuja, Evandro ;

Aura, Claudia ;

Gomez, Henry ;

Dinh, Phuong ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Goldhirsch, Aron ;

Chang, Tsai-Wang ;

Horvath, Zsolt ;

Coccia-Portugal, Maria ;

Domont, Julien ;

Tseng, Ling-Min ;

Kunz, Georg ;

Sohn, Joo Hyuk ;

Semiglazov, Vladimir ;

Lerzo, Guillermo ;

Palacova, Marketa ;

Probachai, Volodymyr ;

Pusztai, Lajos ;

Untch, Michael ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine .

LANCET, 2012, 379 (9816) :633-640

[4] TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial [J].

Bonnefoi, Herve ;

Piccart, Martine ;

Bogaerts, Jan ;

Mauriac, Louis ;

Fumoleau, Pierre ;

Brain, Etienne ;

Petit, Thierry ;

Rouanet, Philippe ;

Jassem, Jacek ;

Blot, Emmanuel ;

Zaman, Khalil ;

Cufer, Tanja ;

Lortholary, Alain ;

Lidbrink, Elisabet ;

Andre, Sylvie ;

Litiere, Saskia ;

Dal Lago, Lissandra ;

Becette, Veronique ;

Cameron, David A. ;

Bergh, Jonas ;

Iggo, Richard .

LANCET ONCOLOGY, 2011, 12 (06) :527-539

[5] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer [J].

Cheang, Maggie C. U. ;

Chia, Stephen K. ;

Voduc, David ;

Gao, Dongxia ;

Leung, Samuel ;

Snider, Jacqueline ;

Watson, Mark ;

Davies, Sherri ;

Bernard, Philip S. ;

Parker, Joel S. ;

Perou, Charles M. ;

Ellis, Matthew J. ;

Nielsen, Torsten O. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10) :736-750

[6] PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients [J].

Contreras, A. ;

Herrera, S. ;

Wang, T. ;

Mayer, I. ;

Forero, A. ;

Nanda, R. ;

Goetz, M. ;

Chang, J. C. ;

Pavlick, A. C. ;

Fuqua, S. A. W. ;

Gutierrez, C. ;

Hilsenbeck, S. G. ;

Li, M. M. ;

Osborne, C. K. ;

Schiff, R. ;

Rimawi, M. F. .

CANCER RESEARCH, 2013, 73

[7] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[8] Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers [J].

Dave, Bhuvanesh ;

Migliaccio, Ilenia ;

Gutierrez, M. Carolina ;

Wu, Meng-Fen ;

Chamness, Gary C. ;

Wong, Helen ;

Narasanna, Archana ;

Chakrabarty, Anindita ;

Hilsenbeck, Susan G. ;

Huang, Jian ;

Rimawi, Mothaffar ;

Schiff, Rachel ;

Arteaga, Carlos ;

Osborne, C. Kent ;

Chang, Jenny C. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) :166-173

[9]

de Azambuja E., 2014, Lancet. Oncol

[10] Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial† [J].

Denkert, C. ;

Loibl, S. ;

Mueller, B. M. ;

Eidtmann, H. ;

Schmitt, W. D. ;

Eiermann, W. ;

Gerber, B. ;

Tesch, H. ;

Hilfrich, J. ;

Huober, J. ;

Fehm, T. ;

Barinoff, J. ;

Jackisch, C. ;

Prinzler, J. ;

Ruediger, T. ;

Erbstoesser, E. ;

Blohmer, J. U. ;

Budczies, J. ;

Mehta, K. M. ;

von Minckwitz, G. .

ANNALS OF ONCOLOGY, 2013, 24 (11) :2786-2793

← 1 2 3 4 5 6 7 →